Pioneering the Next Generation of Genetic Nanomedicines
ViaNautis is exploiting its proprietary technology, polyNaut®, a nanovesicle platform using advanced polymer materials and machine learning, to direct nucleic acid therapeutics to the specific site of action with unparalleled precision.
ViaNautis’ exceptional team of scientists and biotech leaders are building a strong pipeline of innovative products from state of the art facilities in Cambridge UK.
ViaNautis products are enabled by the polyNaut® platform. This proprietary technology uses advanced polymer materials and in silico screening to precisely direct genetic molecules to their intended sites of action.
Genetic medicines are revolutionising the development of new therapeutics for previously untreatable diseases. Modalities such as mRNA, siRNA and gene editing present opportunities for a new generation of advanced therapeutics but require a means of safe and targeted delivery. ViaNautis is deploying polyNaut’s unique properties to deliver these treatments to patients.
News & Events
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
Multi-year collaboration will use ViaNautis’ non-immunogenic polyNaut® nanovesicles that precisely target specific tissues and cell types.
ViaNautis Appoints Ray Jupp as Chief Scientific Officer
ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking biotechnology company at the forefront of genetic therapies, today announces the appointment of Dr Ray Jupp as…